188 related articles for article (PubMed ID: 33138869)
21. The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies.
Haji Ali Afzali H; Street J; Merlin T; Karnon J
Int J Technol Assess Health Care; 2021 Jan; 37():e22. PubMed ID: 33455592
[TBL] [Abstract][Full Text] [Related]
22. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
23. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
24. LEGITIMACY OF MEDICINES FUNDING IN THE ERA OF ACCELERATED ACCESS.
Pace J; Pearson SA; Lipworth W
Int J Technol Assess Health Care; 2017 Jan; 33(6):700-707. PubMed ID: 28893332
[TBL] [Abstract][Full Text] [Related]
25. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
26. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
[TBL] [Abstract][Full Text] [Related]
27. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
28. Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.
McCabe C; Claxton K; O'Hagan A
Int J Technol Assess Health Care; 2008; 24(2):140-5. PubMed ID: 18400115
[TBL] [Abstract][Full Text] [Related]
29. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
[TBL] [Abstract][Full Text] [Related]
30. Access to novel drugs and therapeutics for children and youth: Eliciting citizens' values to inform public funding decisions.
Gauvreau CL; Wight L; Subasri M; Palmer A; Hayeems R; Croker A; Abelson J; Fraser B; Bombard Y; Moore Hepburn C; Wilson MG; Denburg A
Health Expect; 2023 Apr; 26(2):715-727. PubMed ID: 36639959
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of economic evaluations for
Farris M; Goodall S; De Abreu Lourenco R
Int J Technol Assess Health Care; 2023 Jun; 39(1):e38. PubMed ID: 37313789
[TBL] [Abstract][Full Text] [Related]
32. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
33. Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders' capacity, needs, policy areas of demand and perspectives in Nigeria.
Uzochukwu BSC; Okeke C; O'Brien N; Ruiz F; Sombie I; Hollingworth S
Global Health; 2020 Jul; 16(1):58. PubMed ID: 32641066
[TBL] [Abstract][Full Text] [Related]
34. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
35. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
36. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.
Wang T; McAuslane N; Goettsch WG; Leufkens HGM; De Bruin ML
Int J Technol Assess Health Care; 2023 Apr; 39(1):e20. PubMed ID: 37039100
[TBL] [Abstract][Full Text] [Related]
37. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Angelis A; Lange A; Kanavos P
Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
[TBL] [Abstract][Full Text] [Related]
38. Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.
Ducournau P; Irl C; Tatt I; McCarvil M; Gyldmark M
Int J Technol Assess Health Care; 2019 Jan; 35(1):10-16. PubMed ID: 30789111
[TBL] [Abstract][Full Text] [Related]
39. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
Visintin E; Tinelli M; Kanavos P
Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
[TBL] [Abstract][Full Text] [Related]
40. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
